We are live on ! Find out more
CA

Corriente Advisors Portfolio holdings

AUM $9.53M
1-Year Est. Return 805.26%
This Fund
S&P 500
This Quarter Est. Return
+77.69%
1 Year Est. Return
+805.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$186M
AUM Growth
–
Cap. Flow
+$161M
Cap. Flow %
86.37%
Top 10 Hldgs %
91.77%
Holding
17
New
17
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$35M
2
MAXR
Maxar Technologies Inc. Common Stock
MAXR
+$27.9M
3
I
INTELSAT S. A.
I
+$25.6M
4
SPCE icon
Virgin Galactic
SPCE
+$23.5M
5
QURE icon
uniQure
QURE
+$13.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 50.05%
2 Technology 22.58%
3 Industrials 14.96%
4 Materials 2.13%
5 Communication Services 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MAXR
1
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
$42M 22.58%
+2,682,790
New +$27.9M
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$39.3M 21.08%
+192,000
New +$35M
SPCE icon
3
Virgin Galactic
SPCE
$329M
$27.9M 14.96%
+120,586
New +$23.5M
QURE icon
4
uniQure
QURE
$2.77B
$18.1M 9.72%
+252,500
New +$13.9M
TPTX
5
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$17.8M 9.54%
+285,000
New +$13.6M
I
6
DELISTED
INTELSAT S. A.
I
$11.5M 6.16%
+1,631,227
New +$25.6M
CUE icon
7
Cue Biopharma
CUE
$131M
$4.52M 2.43%
+9,500
New +$2.98M
ATXS
8
DELISTED
Astria Therapeutics
ATXS
$3.65M 1.96%
+102,847
New +$3.24M
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.18M 1.71%
+40,000
New +$2.37M
EIGR
10
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.04M 1.63%
+6,797
New +$2.41M
SPCE.WS
11
CALL
DELISTED
Virgin Galactic Holdings, Inc. Warrants, each whole warrant exercisable for one share of Common Stoc
SPCE.WS
$2.92M 1.57%
+252,983
New +$607K
APTO
12
DELISTED
Aptose Biosciences, Inc.
APTO
$2.57M 1.38%
+1,007
New +$1.31M
EQX icon
13
Equinox Gold
EQX
$6.8B
$2.31M 1.24%
+300,000
New +$1.86M
DIS icon
14
Walt Disney
DIS
$170B
$2.17M 1.17%
+15,000
New +$2.09M
RCKT icon
15
Rocket Pharmaceuticals
RCKT
$376M
$2.02M 1.09%
+88,927
New +$1.49M
BLU
16
DELISTED
BELLUS Health Inc.
BLU
$1.67M 0.9%
+220,000
New +$1.5M
GFI icon
17
Gold Fields
GFI
$28.6B
$1.65M 0.89%
+250,000
New +$1.42M

Similar funds

SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Corriente Advisors's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Corriente Advisors, which disclosed 17 positions worth $186M. Its ten largest holdings account for 92% of the portfolio.

Its largest position is Reata Pharmaceuticals, Inc. Class A Common Stock: 192,000 shares worth $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, followed by Technology and Industrials.

  • Corriente Advisors's largest Q4 2019 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 192,000 shares worth $39.3M.
  • Corriente Advisors's ten largest holdings make up 92% of its $186M portfolio in Q4 2019.
  • Corriente Advisors disclosed 17 positions in Q4 2019, its first 13F filing on record.

Based on Corriente Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.